MedPath

Cisplatin

Generic Name
Cisplatin
Brand Names
Platinol
Drug Type
Small Molecule
Chemical Formula
Cl2H6N2Pt
CAS Number
15663-27-1
Unique Ingredient Identifier
Q20Q21Q62J
Background

Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication

For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions
Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
Associated Therapies
-
Clinical Trials
Related News

Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy

Phase 3
Terminated
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Drug: Capmatinib
Drug: Pemetrexed
Drug: Osimertinib
Drug: Cisplatin
Drug: Carboplatin
First Posted Date
2021-03-25
Last Posted Date
2024-03-05
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
6
Registration Number
NCT04816214
Locations
🇸🇬

Novartis Investigative Site, Singapore, Singapore

Intratumoral Cisplatin for Resectable NSCLC

Phase 1
Recruiting
Conditions
Non-Small Cell Lung Cancer
Interventions
Drug: cis-diamminedichloroplatinum
First Posted Date
2021-03-22
Last Posted Date
2022-05-23
Lead Sponsor
University of Vermont
Target Recruit Count
10
Registration Number
NCT04809103
Locations
🇺🇸

University of Vermont, Burlington, Vermont, United States

Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)

Phase 3
Recruiting
Conditions
Esophageal Squamous Cell Carcinoma
Interventions
Biological: Pembrolizumab
Radiation: neoadjuvant chemoradiotherapy
Drug: Paclitaxel
Drug: Cisplatin
First Posted Date
2021-03-19
Last Posted Date
2022-06-01
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
342
Registration Number
NCT04807673
Locations
🇨🇳

Department of minimally invasive esophageal surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer

Phase 3
Withdrawn
Conditions
Cervical Cancer
Interventions
Drug: HLX10
Drug: Paclitaxel
Drug: Cisplatin
Drug: Carboplatin
Drug: Placebo to HLX10
First Posted Date
2021-03-19
Last Posted Date
2022-05-05
Lead Sponsor
Shanghai Henlius Biotech
Registration Number
NCT04806945
Locations
🇨🇳

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China

Toripalimab With Paclitaxel and Cisplatin as Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma

Phase 2
Recruiting
Conditions
Esophageal Squamous Cell Cancer
Interventions
Drug: Toripalimab
Drug: Paclitaxel
Drug: Cisplatin
First Posted Date
2021-03-18
Last Posted Date
2023-02-01
Lead Sponsor
Peking University
Target Recruit Count
53
Registration Number
NCT04804696
Locations
🇨🇳

Beijing Cancer Hospital / Peking University Cancer Hospital, Beijing, Beijing, China

A Study of HB002.1T Plus Chemotherapy in Subjects With Solid Tumor

First Posted Date
2021-03-17
Last Posted Date
2021-07-28
Lead Sponsor
Huabo Biopharm Co., Ltd.
Target Recruit Count
72
Registration Number
NCT04802980
Locations
🇨🇳

Shanghai East Hospital, Shanghai, Shanghai, China

Pamiparib and Low Dose Temozolomide In Patients With Platinum Sensitive Biliary Tract Cancer

Phase 2
Withdrawn
Conditions
Platinum-Sensitive Biliary Tract Cancer
Interventions
Drug: Cisplatin
Drug: Pamiparib
Drug: Gemcitabine
Drug: Temozolomide
Drug: Oxaliplatin
First Posted Date
2021-03-12
Last Posted Date
2022-06-01
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Registration Number
NCT04796454

Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab (CK-301) in First Line Metastatic Non-squamous Non-Small Cell Lung Cancer

Phase 3
Terminated
Conditions
Metastatic Non-squamous Non Small Cell Lung Cancer
Interventions
Drug: Cisplatin
Drug: Cosibelimab
Drug: Carboplatin
Drug: Pemetrexed
Dietary Supplement: Folic acid 350-1000 μg
Dietary Supplement: Vitamin B12 1000 μg
Drug: Dexamethasone 4mg
First Posted Date
2021-03-08
Last Posted Date
2024-08-20
Lead Sponsor
Checkpoint Therapeutics, Inc.
Target Recruit Count
25
Registration Number
NCT04786964
Locations
🇹🇭

Research Site, Chiang Mai, Thailand

Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer

Phase 3
Active, not recruiting
Conditions
Extensive-stage Small Cell Lung Cancer
Interventions
Drug: Durvalumab
Drug: Cisplatin
Drug: Carboplatin
Drug: Etoposide
First Posted Date
2021-03-01
Last Posted Date
2024-10-18
Lead Sponsor
AstraZeneca
Target Recruit Count
152
Registration Number
NCT04774380
Locations
🇹🇷

Research Site, Pamukkale, Turkey

Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC

Phase 3
Conditions
Non-Small-Cell Lung Cancer
Interventions
Drug: Placebo
Drug: Camrelizumab
Drug: Cisplatin
Drug: Carboplatin
Drug: Pemetrexed
Drug: Paclitaxel
Drug: Albumin paclitaxel
First Posted Date
2021-02-24
Last Posted Date
2021-02-24
Lead Sponsor
Guangdong Association of Clinical Trials
Target Recruit Count
200
Registration Number
NCT04768075
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy